Tag: CSE:RVV

January 26, 2021

First Psychedelics ETF Officially Launches in Canadian Market

Horizons ETFs will begin offering investors exposure to the rising psychedelics market with the launch of a brand-new fund.
January 12, 2021

Psychedelics Stocks to Watch

A growing list of the available psychedelics stocks to watch out for from the Investing News Network.
August 26, 2020

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive to also explore FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19
May 13, 2020

Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives

Revive Therapeutics is pleased to provide a corporate update on its pharmaceutical programs for Bucillamine in the treatment of the...
April 29, 2020

Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program

Revive Therapeutics is pleased to provide further insight on its plans for its psilocybin-based pharmaceutical program.
April 23, 2020

Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial

Revive Therapeutics (CSE:RVV) has received positive feedback from the U.S. FDA in response to the company’s pre-IND meeting that was...
April 21, 2020

Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison

Revive Therapeutics (CSE:RVV) has entered into a SRPA with the University of Wisconsin-Madison to evaluate novel formulations and drug delivery...